The Covid precedent gives free rein to speculation with the values that can take advantage of the threat of monkeypox. Bavarian Nordic monopolizes the biggest spotlights, but not the biggest rises.
Vaccines, drugs and diagnostic tests are once again part of the jargon of investors, and unlike the previous two years, it is not precisely as a result of Covid. Monkeypox grabs headlines, and its spread to nearly twenty countries has led health authorities to take measures with a palpable economic impact on listed companies. Even stock market giants such as Roche have launched into the development of diagnostic tests for this disease.
The first initiatives of the authorities have been the purchase or the announcement of the acquisition of vaccines. The United States and the United Kingdom have already sealed supply contracts with the Danish Bavarian Nordic, responsible for “the only smallpox vaccine that has extended the indication to monkeypox.” Other countries, such as Spain, have expressed their intention to join this acquisition of vaccines.
All this news makes Bavarian Nordic the most popular recipient of share purchases by investors who see options to capitalize on the alarm generated by the spread of monkeypox. The shares of the Danish company have soared up to 70% in four days on the Copenhagen Stock Exchange.
Bavarian Nordic stands out on the stock market thanks to its vaccine. But expectations that some of the vaccines or treatments developed against other diseases could be adapted to monkeypox have fueled even more raises for other biopharmaceutical companies.
The most vertical revaluations as a result of the alarm created by the spread of monkeypox are carried out by GeoVax Labs. The American company, listed on the Nasdaq, came to fly 290% in one week, before halving this rally . The company is specialized in the development of vaccines and immunotherapy treatments, such as those made for viruses such as Zika or Ebola.
The avalanche of purchases with a speculative profile in companies that could monetize the alarm generated by monkeypox has shot up to 70% another Nasdaq stock such as Siga Technologies. The pharmaceutical company is specialized in the treatment of human smallpox caused by the smallpox virus.
Without abandoning the Nasdaq, investors have reacted in recent days to the latest health alert with notable increases also in the price of Emergent Biosolutions. Its shares soared 35% in five days.
The share purchases unleashed by the spread of monkeypox have Bavarian Nordic as the main recipient in Europe, and GeoVax Labs, Siga Technologies and Emergent Biosolutions on the US Nasdaq. The contagion of the stock market rises also reaches Asia, and especially the biopharmaceuticals listed on Chinese equities.
With the precedent of Covid, the speculative movements of investors who have launched into the purchase of shares in securities that could benefit from a greater spread of monkeypox has caused companies that have exploded on the stock market such as Changchun BCHT Biotechnology to have to admit that they do not have products capable of preventing the disease.
Among the most revalued Chinese laboratories in recent days in the heat of the news about monkeypox, Shanghai ZJ Bio-Tech stands out, soaring more than 40%, Changchun BCHT Biotechnology, with advances of more than 30%, Sansure Biotech and Xidian Pharmaceutical , relaunched more than 20% on the stock market, Jiangsu Bioperfectus Technologies, with gains close to 20%, and Hangzhou Biotest Biotec, revalued close to 10%.